Dissociation of the pharmacological effects of THC by mTOR blockade

Neuropsychopharmacology

Volumn 38, Issue 7, 2013, Pages 1334-1343

  Puighermanal, Emma ^a,d   Busquets Garcia, Arnau ^a   Gomis González, Maria ^a   Marsicano, Giovanni ^b,c   Maldonado, Rafael ^a   Ozaita, Andrés ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b INSTITUT FRANÇOIS MAGENDIE   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

anxiety like behavior; CB1 cannabinoid receptor; delta9 tetrahydrocannabinol; memory; mTOR pathway; tolerance

Indexed keywords

CANNABINOID 1 RECEPTOR; DRONABINOL; MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GABAERGIC SYSTEM; HYPOTHERMIA; KNOCKOUT MOUSE; LOCOMOTION; LONG TERM CARE; MALE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY;

AMNESIA; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; DOWN-REGULATION; DRONABINOL; DRUG INTERACTIONS; DRUG TOLERANCE; HYPOTHERMIA; LOCOMOTION; MALE; MICE; MICE, KNOCKOUT; NOCICEPTION; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84878610582     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.31     Document Type: Article

References (58)

1. Bellocchio L, Lafenetre P, Cannich A, Cota D, Puente N, Grandes P et al (2010). Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 13: 281-283.
2. Blundell J, Kouser M, Powell CM (2008). Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation. Neurobiol Learn Mem 90: 28-35.
3. Boucher AA, Vivier L, Metna-Laurent M, Brayda-Bruno L, Mons N, Arnold JC et al (2009). Chronic treatment with Delta (9)-tetrahydrocannabinol impairs spatial memory and reduces zif268 expression in the mouse forebrain. Behav Pharmacol 20: 45-55.
4. Bruel-Jungerman E, Rampon C, Laroche S (2007). Adult hippocampal neurogenesis, synaptic plasticity and memory: facts and hypotheses. Rev Neurosci 18: 93-114.
5. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A (2011). Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70: 479-486.
6. Castellano C, Rossi-Arnaud C, Cestari V, Costanzi M (2003). Cannabinoids and memory: animal studies. Curr Drug Targets CNS Neurol Disord 2: 389-402.
7. Dancey JE (2005). Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 14: 313-328.
8. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C et al (2003). Regulation of extracellular signalregulated kinase by cannabinoids in hippocampus. J Neurosci 23: 2371-2382.
9. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S (2011). Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 4: 476-495.
10. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ et al (2008). Reversal of learning deficits in a Tsc2/- mouse model of tuberous sclerosis. Nat Med 14: 843-848.
11. Fan N, Yang H, Zhang J, Chen C (2010). Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Delta9-THC exposure-impaired hippocampal synaptic plasticity. J Neurochem 112: 691-702.
12. Guertin DA, Sabatini DM (2009). The pharmacology of mTOR inhibition. Sci Signal 2: 24.
13. Hoeffer CA, Klann E (2010). mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33: 67-75.
14. Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR (2007). Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learn Mem 14: 63-74.
15. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
16. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J et al (1998). Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125: 1567-1577.
17. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X et al (2006). TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
18. Jaworski J, Sheng M (2006). The growing role of mTOR in neuronal development and plasticity. Mol Neurobiol 34: 205-219.
19. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G (1997). Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 16: 3693-3704.
20. Katona I, Sperlagh B, S?k A, Kafalvi A, Vizi ES, Mackie K et al (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544-4558.
21. Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D et al (2006). Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26: 5628-5637.
22. Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M et al (2006). The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26: 2991-3001.
23. Kim HJ, Waataja JJ, Thayer SA (2008). Cannabinoids inhibit network-driven synapse loss between hippocampal neurons in culture. J Pharmacol Exp Ther 325: 850-858.
24. Krab LC, Goorden SM, Elgersma Y (2008). Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases. Trends Genet 24: 498-510.
25. Mackie K (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168: 299-325.
26. Maldonado R, Berrendero F, Ozaita A, Robledo P (2011). Neurochemical basis of cannabis addiction. Neuroscience 181: 1-17.
27. Marsicano G, Lafenetre P (2009). Roles of the endocannabinoid system in learning and memory. Curr Top Behav Neurosci 1: 201-230.
28. Marsicano G, Lutz B (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11: 4213-4225.
29. Martin BR, Sim-Selley LJ, Selley DE (2004). Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 25: 325-330.
30. Milligan G, Smith NJ (2007). Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 28: 615-620.
31. Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schutz G et al (2007). Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol 5: e269.
32. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R et al (2006). The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51: 455-466.
33. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR (1999). Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344: 427-431.
34. Ozaita A, Puighermanal E, Maldonado R (2007). Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 102: 1105-1114.
35. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63: 569-611.
36. Pertwee RG (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
37. Pertwee RG (2012). Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 367: 3353-3363.
38. Piomelli D (2005). The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6: 672-679.
39. Puighermanal E, Busquets-Garcia A, Maldonado R, Ozaita A (2012). Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philos Trans R Soc Lond B Biol Sci 367: 3254-3263.
40. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A (2009). Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12: 1152-1158.
41. Rey AA, Purrio M, Viveros MP, Lutz B (2012). Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 34: 2624-2634.
42. Richter JD, Klann E (2009). Making synaptic plasticity and memory last: mechanisms of translational regulation. Genes Dev 23: 1-11.
43. Rini BI (2008). Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 14: 1286-1290.
44. Rubino T, Sala M, Vigano D, Braida D, Castiglioni C, Limonta V et al (2007). Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology 32: 2036-2045.
45. Rubino T, Vigano D, Premoli F, Castiglioni C, Bianchessi S, Zippel R et al (2006). Changes in the expression of G proteincoupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade. Mol Neurobiol 33: 199-213.
46. Ruehle S, Rey AA, Remmers F, Lutz B (2012). The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol 26: 23-39.
47. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E et al (2010). Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 30: 694-702.
48. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G et al (1995). An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 270: 3726-3731.
49. Sim-Selley LJ (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91-119.
50. Skosnik PD, Edwards CR, O'Donnell BF, Steffen A, Steinmetz JE, Hetrick WP (2008). Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning. Neuropsychopharmacology 33: 1432-1440.
51. Smith TH, Sim-Selley LJ, Selley DE (2010). Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 160: 454-466.
52. Steindel F, Lerner R, Haring M, Ruehle S, Marsicano G, Lutz B et al (2013). Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus. J Neurochem (e-pub ahead of print 5 January 2013; doi:10.1111/jnc.12137).
53. Thorat SN, Bhargava HN (1994). Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol 260: 5-13.
54. Troca-Mar?n JA, Alves-Sampaio A, Montesinos ML (2012). Deregulated mTOR-mediated translation in intellectual disability. Prog Neurobiol 96: 268-282.
55. Viveros MP, Marco EM, File SE (2005). Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81: 331-342.
56. Wager-Miller J, Westenbroek R, Mackie K (2002). Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 121: 83-89.
57. Wilson RI, Nicoll RA (2002). Endocannabinoid signaling in the brain. Science 296: 678-682.
58. Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S (2011). Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci 5: 57.